Currently, we are developing six new drugs to treat childhood cancers. Of these drugs, we filed a New Drug Application for Crisantaspase, an antineoplastic enzyme preparation, in December 2015. We continue to strive to enhance our orphan drug pipeline, particularly against childhood cancers, in which large pharmaceutical companies are reluctant to be involved. Furthermore, we are committed to addressing unmet medical needs through drug development applying methods in epigenetics.

Childhood Cancers

Hepatic/Biliary disease